Kumho Ht, Inc.

Dinona Inc.

Aprogen Inc.

Aprogen Kic Inc.

Aprogen Medicines Inc.

Sangsoon Yoon

Yoo Ri Moon

Gil Yong Ji

Kwon Pyo Hong

Jeong Won Hong

Eun Jung Kim

George Kopsidas

David S Wilson, Jr

Vincent Batori

Soseul Kim

Irene Koukoulas

Briony Cristiano

Da Bin Choi

Jung Sik Kim

Hyung-Geun Song

Eui Sup Lee

Young Hoon Lim

Mi Hyang Shin

The present invention relates to an anti-ICAM-1 antibody or an antigen-binding fragment thereof that specifically binds to ICAM-1, and the use thereof. Specifically, provided are an anti-ICAM-1 antibody or an antigen-binding fragment thereof, a pharmaceutical composition for regulating differentiation and/or function of dendritic cell, and a pharmaceutical composition for preventing and/or treating immune cell-mediated disease, the composition comprising the antibody or the antigen-binding fragment as an active ingredient.

Antibody specifically binding to ICAM-1 and use thereof

The present invention relates to an antibody or an antigen-binding fragment thereof specifically binding to CD66c which is expressed in myeloid-derived suppressor cell (MDSC) and a use thereof, and specifically to an antibody or an antigen-binding fragment thereof specifically binding to CD66c, a pharmaceutical composition or a diagnosing composition including the same. The anti-CD66c antibody of the present invention can be used usefully for the treatment of various diseases by targeting MDSC which can induce the immunosuppression.

Use for preventing and treating myeloid-derived suppressor cell-related diseases

The present invention relates to an anti-CD40 antibody binding specifically to CD40 and use thereof and, particularly, provides an anti-CD40 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same antibody or fragment as an effective ingredient for prevention and/or treatment of cancer, cancer metastasis, infection, and/or immune deficiency diseases.

Antibody binding specifically to CD40 and use thereof

Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.

Antibody binding to carbonic anhydrase and use thereof

Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

Anti-CD43 antibody and use thereof for cancer treatment

The present invention relates to an anti-CD66c antibody and its use for treating cancer, and more particularly, it is possible to induce T-cell activation or humoral immune response using an antibody specifically recognizing CD66c. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell and the antibody or antigen-binding fragment thereof is used for alleviation, prevention, treatment or diagnosis of CD66c-related disease.

Antibody binding specifically to CD66c and use thereof

A use of prevention or treatment of lung cancer including an antibody specifically recognizing CD66c in lung cancer or its antigen-binding fragment and a chemotherapeutic agent is provided.

Composition for preventing or treating lung cancer comprising antibody against CD66C and chemotherapeutic agent

Growing community of inventors

Seoul, South Korea

Sangsoon Yoon